Edition:
United States

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

5.58USD
16 Feb 2018
Change (% chg)

$0.06 (+1.09%)
Prev Close
$5.52
Open
$5.49
Day's High
$5.61
Day's Low
$5.46
Volume
413,179
Avg. Vol
649,632
52-wk High
$8.29
52-wk Low
$3.50

Latest Key Developments (Source: Significant Developments)

TherapeuticsMD Submits New Drug Application For TX-001HR
Thursday, 28 Dec 2017 04:30pm EST 

Dec 28 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TX-001HR.THERAPEUTICSMD - EXPECTS TO LEARN OF ACCEPTANCE OF NDA FROM FDA ABOUT 74 DAYS AFTER NDA SUBMISSION.  Full Article

Therapeuticsmd Announces FDA Acceptance Of New Drug Application And PDUFA Date For TX-004HR
Tuesday, 19 Dec 2017 04:36pm EST 

Dec 19 (Reuters) - Therapeuticsmd Inc ::THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-004HR.THERAPEUTICSMD INC - PDUFA TARGET ACTION DATE SET OF MAY 29, 2018.THERAPEUTICSMD INC - COMPANY CURRENTLY PLANS TO LAUNCH TX-004HR IN Q3 OF 2018 IF APPROVAL OCCURS ON OR BEFORE PDUFA TARGET ACTION DATE.  Full Article

TherapeuticsMD Announces Resubmission Of New Drug Application For TX-004HR
Wednesday, 29 Nov 2017 04:30pm EST 

Nov 29 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR TX-004HR.THERAPEUTICSMD INC - COMPANY EXPECTS TO LEARN OF ACCEPTANCE OF NDA RESUBMISSION WITHIN 30 CALENDAR DAYS.  Full Article

TherapeuticsMD reports Q3 loss per share of $0.07
Monday, 6 Nov 2017 06:05am EST 

Nov 6 (Reuters) - Therapeuticsmd Inc ::TherapeuticsMD announces third quarter 2017 financial results.Q3 loss per share $0.07.Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Q3 revenue $4.4 million versus i/b/e/s view $5.2 million.  Full Article

TherapeuticsMD announces plan to resubmit the new drug application for TX-004HR
Monday, 6 Nov 2017 06:00am EST 

Nov 6 (Reuters) - TherapeuticsMD Inc :TherapeuticsMD Inc announces plan to resubmit the new drug application for TX-004HR.TherapeuticsMD Inc - Division of bone,reproductive & urologic products, US FDA agreed to NDA resubmission for TX-004HR without additional pre-approval study​.TherapeuticsMD Inc - ‍on Nov 3 co participated in an in-person meeting with division of bone, reproductive, and urologic products of US FDA​.TherapeuticsMD Inc - ‍co will commit to conduct a post-approval observational study​.  Full Article

TherapeuticsMD prices offering of 12.4 mln shares at $5.65 per share
Monday, 25 Sep 2017 10:28pm EDT 

Sept 25 (Reuters) - TherapeuticsMD Inc - :TherapeuticsMD announces pricing of common stock offering.TherapeuticsMD - Announced pricing of an underwritten public offering of 12.4 million shares of its common stock at a price to public of $5.65 per share.  Full Article

TherapeuticsMD announces public offering of 12.4 mln shares of common stock
Monday, 25 Sep 2017 04:52pm EDT 

Sept 25 (Reuters) - TherapeuticsMD Inc :TherapeuticsMD announces public offering of 12.4 million shares of common stock.  Full Article

TherapeuticsMD Inc says to move stock listing to Nasdaq Global Select Market
Monday, 25 Sep 2017 07:12am EDT 

Sept 25 (Reuters) - TherapeuticsMD Inc :TherapeuticsMD Inc - announced that it will voluntarily move its stock exchange listing to Nasdaq Global Select Market from NYSE American Llc.  Full Article

‍TherapeuticsMD announces submission of additional endometrial safety information to new drug application for TX-004HR​
Thursday, 14 Sep 2017 04:30pm EDT 

Sept 14 (Reuters) - TherapeuticsMD Inc :‍TherapeuticsMD announces submission of additional endometrial safety information to new drug application for TX-004HR​.TherapeuticsMD Inc - ‍Company currently plans to re-submit NDA for TX-004HR shortly after meeting​.TherapeuticsMD Inc - ‍Scheduled a formal meeting with FDA for November 3, 2017 regarding TX-004HR​.  Full Article

TherapeuticsMD • Q2 loss per share $0.10
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - TherapeuticsMD Inc :TherapeuticsMD announces second quarter 2017 financial results.Q2 loss per share $0.10.Q2 revenue $4.3 million versus I/B/E/S view $4.9 million.Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-TherapeuticsMD Submits New Drug Application For TX-001HR

* THERAPEUTICSMD ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TX-001HR